我們已在上線！進一步了解

Prelude Therapeutics

PRLD

市值 US$2.6億

3.26 USD

-0.06

1.81%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

3.21

-0.05

1.53%

1天

-1.81%

5天

-16.62%

1個月

-27.07%

3個月

-22.01%

6個月

-26.41%

今年迄今

19.41%

1年

148.85%

5年

-79.26%

10年

-87.56%

關於： Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

員工： 79

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 42.9%

中性 57.1%

負面 0%

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

WILMINGTON, Del., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Chardan Healthcare Conference taking place in New York City on October 20, 2026.

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

Zacks Investment Research

Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround

Prelude Therapeutics (PRLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer

Combination cohorts are part of Prelude's Phase 1 trial evaluating PRT13722 in patients with HR+/HER2- breast cancer, on track to initiate enrollment in the fourth quarter of 2026

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

WILMINGTON, Del., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the H.C. Wainwright 28th Annual Global Investment Conference, taking place in New York City September 14-16, 2026.

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

WILMINGTON, Del., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company to proceed with a Phase 1 study under its Investigational New Drug Application (IND) for PRT13722, an oral KAT6A selective degrader being developed for the treatment of patients with HR+/HER2- breast cancer.

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

Zacks Investment Research

Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?

The consensus price target hints at a 58.4% upside potential for Prelude Therapeutics (PRLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?

Zacks Investment Research

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why

Prelude Therapeutics (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why

Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Zacks Investment Research

Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Prelude Therapeutics (PRLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet

查看新聞排名

價格圖表採用Lightweight Charts™實作